Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

GLP-1 supplement makers claim that their products work similarly to weight loss injections like Ozempic. Here's what experts ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...

Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...

"There is a clear association between the use of GLPs and increased risks of food retention during upper endoscopy," Mathur ...

Folks who take one of the popular GLP-1 weight-loss meds might end up with a cancelled endoscopy or colonoscopy New research ...

The quest for effective and safe weight loss solutions has long been a focus of medical research. In recent years, a novel ...

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...